

# Hidemitsu Kitamura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/960173/publications.pdf>

Version: 2024-02-01

24  
papers

2,073  
citations

516710

16  
h-index

642732

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combination therapy for hepatocellular carcinoma with diacylglycerol kinase alpha inhibition and anti-programmed cell death-1 ligand blockade. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 889-903.	4.2	8
2	<sc>IFN</sc> $\alpha$ 2-mediated <sc>NK2R</sc> expression is related to the malignancy of colon cancer cells. <i>Cancer Science</i> , 2022, , .	3.9	7
3	CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
4	MicroRNA 16-5p is upregulated in calorie-restricted mice and modulates inflammatory cytokines of macrophages. <i>Gene</i> , 2020, 725, 144191.	2.2	31
5	IL6 Modulates the Immune Status of the Tumor Microenvironment to Facilitate Metastatic Colonization of Colorectal Cancer Cells. <i>Cancer Immunology Research</i> , 2019, 7, 1944-1957.	3.4	61
6	L-Type Calcium Channel-Mediated Zinc Wave Is Involved in the Regulation of IL-6 by Stimulating Non-IgE with LPS and IL-33 in Mast Cells and Dendritic Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 87-93.	1.4	10
7	Inhibition of diacylglycerol kinase alpha to augment antitumor effector T cells in tumor-bearing host.. <i>Journal of Clinical Oncology</i> , 2019, 37, 293-293.	1.6	0
8	Interleukin $\alpha$ 6/<sc>STAT</sc>3 signaling as a promising target to improve the efficacy of cancer immunotherapy. <i>Cancer Science</i> , 2017, 108, 1947-1952.	3.9	189
9	Lack of interleukin $\alpha$ 6 in the tumor microenvironment augments type $\alpha$ 1 immunity and increases the efficacy of cancer immunotherapy. <i>Cancer Science</i> , 2017, 108, 1959-1966.	3.9	61
10	Ecrq4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. <i>Oncolmmunology</i> , 2016, 5, e1242547.	4.6	14
11	IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 193-204.	4.2	83
12	IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway. <i>Scientific Reports</i> , 2015, 5, 13650.	3.3	18
13	Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): Preparation and immunological analysis of vaccine efficacy. <i>Immunology Letters</i> , 2015, 163, 102-112.	2.5	10
14	Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1690-1694.	2.9	14
15	Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. <i>Immunology Letters</i> , 2014, 158, 175-182.	2.5	9
16	Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. <i>Immunology Letters</i> , 2014, 161, 20-30.	2.5	24
17	The Key Role of IL-6 $\alpha$ “Arginase Cascade for Inducing Dendritic Cell $\alpha$ “Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice. <i>Journal of Immunology</i> , 2013, 190, 812-820.	0.8	65
18	Neuropeptide Signaling Activates Dendritic Cell-Mediated Type 1 Immune Responses through Neurokinin-2 Receptor. <i>Journal of Immunology</i> , 2012, 188, 4200-4208.	0.8	22

#	ARTICLE	IF	CITATIONS
19	Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cell responses. <i>European Journal of Immunology</i> , 2012, 42, 2060-2072.	2.9	119
20	First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. <i>Cancer Science</i> , 2012, 103, 150-153.	3.9	53
21	IFN- $\gamma$ elevates airway hyperresponsiveness via upregulation of neurokinin A/neurokinin-2 receptor signaling in a severe asthma model. <i>European Journal of Immunology</i> , 2012, 42, 393-402.	2.9	25
22	IL-6-STAT3 Controls Intracellular MHC Class II $\beta$ Dimer Level through Cathepsin S Activity in Dendritic Cells. <i>Immunity</i> , 2005, 23, 491-502.	14.3	191
23	IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation. <i>Journal of Immunology</i> , 2004, 173, 3844-3854.	0.8	444
24	The Natural Killer T (NKT) Cell Ligand $\alpha$ -Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells. <i>Journal of Experimental Medicine</i> , 1999, 189, 1121-1128.	8.5	588